Roche Holding AG (Roche Holding AG) Days Inventory

: 172.29 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

Days Inventory is also known as Days Sales of Inventory (DSI). Roche Holding AG's Average Total Inventories for the six months ended in Dec. 2023 was $9,198 Mil. Roche Holding AG's Cost of Goods Sold for the six months ended in Dec. 2023 was $9,743 Mil. Hence, Roche Holding AG's Days Inventory for the six months ended in Dec. 2023 was 172.29.

The historical rank and industry rank for Roche Holding AG's Days Inventory or its related term are showing as below:

RHHBY' s Days Inventory Range Over the Past 10 Years
Min: 126.06 Med: 152.43 Max: 186.16
Current: 184.84

During the past 13 years, Roche Holding AG's highest Days Inventory was 186.16. The lowest was 126.06. And the median was 152.43.

RHHBY's Days Inventory is ranked worse than
61.74% of 975 companies
in the Drug Manufacturers industry
Industry Median: 157.96 vs RHHBY: 184.84

Roche Holding AG's Days Inventory increased from Dec. 2022 (150.14) to Dec. 2023 (172.29). It might indicate that Roche Holding AG's sales slowed down.

Inventory Turnover measures how fast the company turns over its inventory within a year. Roche Holding AG's Inventory Turnover for the six months ended in Dec. 2023 was 1.06.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Roche Holding AG's Inventory-to-Revenue for the six months ended in Dec. 2023 was 0.27.

Roche Holding AG Days Inventory Historical Data

The historical data trend for Roche Holding AG's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

125.44

142.92

140.94

151.73

175.58

Roche Holding AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Inventory																138.35	154.97	150.14	193.44	172.29

Competitive Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG Days Inventory Distribution

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Days Inventory distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Days Inventory falls into.

Roche Holding AG Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Roche Holding AG's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (9236.797	+	8960.453)	/	2 )	/	18914.2	*	365
=	9098.625					/	18914.2	*	365
=	175.58

Roche Holding AG's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Jun. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (9435.806	+	8960.453)	/	2 )	/	9743.293	*	365 / 2
=	9198.1295					/	9743.293	*	365 / 2
=	172.29

Roche Holding AG (OTCPK:RHHBY) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Roche Holding AG's Inventory Turnover for the six months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	9743.293	/	9198.1295
	=	1.06

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Roche Holding AG's Inventory to Revenue for the six months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	9198.1295	/	34487.743
	=	0.27

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Roche Holding AG Days Inventory Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG (Roche Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

RHHVF:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.